These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 29281872)
21. Local Recurrence After Primary Proton Beam Therapy in Uveal Melanoma: Risk Factors, Retreatment Approaches, and Outcome. Seibel I; Cordini D; Rehak M; Hager A; Riechardt AI; Böker A; Heufelder J; Weber A; Gollrad J; Besserer A; Joussen AM Am J Ophthalmol; 2015 Oct; 160(4):628-36. PubMed ID: 26133249 [TBL] [Abstract][Full Text] [Related]
22. Ki67 is a better marker than PRAME in risk stratification of BAP1-positive and BAP1-loss uveal melanomas. Donizy P; Spytek M; Krzyziński M; Kotowski K; Markiewicz A; Romanowska-Dixon B; Biecek P; Hoang MP Br J Ophthalmol; 2024 Jun; 108(7):1005-1010. PubMed ID: 37734766 [TBL] [Abstract][Full Text] [Related]
23. Maximizing local tumor control and survival after proton beam radiotherapy of uveal melanoma. Egger E; Schalenbourg A; Zografos L; Bercher L; Boehringer T; Chamot L; Goitein G Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):138-47. PubMed ID: 11516863 [TBL] [Abstract][Full Text] [Related]
24. Prognostic Value of BAP1 and Preferentially Expressed Antigen in Melanoma (PRAME) Immunohistochemistry in Uveal Melanomas. Han LM; Lee KW; Uludag G; Seider MI; Afshar AR; Bloomer MM; Pekmezci M Mod Pathol; 2023 Apr; 36(4):100081. PubMed ID: 36788079 [TBL] [Abstract][Full Text] [Related]
26. Tissue-specific significance of BAP1 gene mutation in prognostic prediction and molecular taxonomy among different types of cancer. Wang XY; Wang Z; Huang JB; Ren XD; Ye D; Zhu WW; Qin LX Tumour Biol; 2017 Jun; 39(6):1010428317699111. PubMed ID: 28618948 [TBL] [Abstract][Full Text] [Related]
32. 20-year assessment of metastatic latency and subsequent time to death after proton therapy for uveal melanomas. Bellocq D; Roy P; Kodjikian L; Mathis T; Nguyen AM; Herault J; Rivoire M; Négrier S; Thariat J; Grange JD Melanoma Res; 2020 Jun; 30(3):272-278. PubMed ID: 30320630 [TBL] [Abstract][Full Text] [Related]
33. Loss of BAP1 expression in metastatic tumor tissue is an event of poor prognosis in patients with metastatic clear cell renal cell carcinoma. da Costa WH; Fares AF; Bezerra SM; Morini MA; de Toledo Benigno LA; Clavijo DA; Fornazieri L; Rocha MM; da Cunha IW; de Cassio Zequi S Urol Oncol; 2019 Jan; 37(1):78-85. PubMed ID: 30446457 [TBL] [Abstract][Full Text] [Related]
34. Survival in patients with presymptomatic diagnosis of metastatic uveal melanoma. Kim IK; Lane AM; Gragoudas ES Arch Ophthalmol; 2010 Jul; 128(7):871-5. PubMed ID: 20625048 [TBL] [Abstract][Full Text] [Related]
36. Comparing the Prognostic Value of BAP1 Mutation Pattern, Chromosome 3 Status, and BAP1 Immunohistochemistry in Uveal Melanoma. van de Nes JA; Nelles J; Kreis S; Metz CH; Hager T; Lohmann DR; Zeschnigk M Am J Surg Pathol; 2016 Jun; 40(6):796-805. PubMed ID: 27015033 [TBL] [Abstract][Full Text] [Related]
37. BAP1 germline mutation in two first grade family members with uveal melanoma. Maerker DA; Zeschnigk M; Nelles J; Lohmann DR; Worm K; Bosserhoff AK; Krupar R; Jägle H Br J Ophthalmol; 2014 Feb; 98(2):224-7. PubMed ID: 24187051 [TBL] [Abstract][Full Text] [Related]
38. Uveal melanoma treated with iodine-125 episcleral plaque: an analysis of dose on disease control and visual outcomes. Perez BA; Mettu P; Vajzovic L; Rivera D; Alkaissi A; Steffey BA; Cai J; Stinnett S; Dutton JJ; Buckley EG; Halperin E; Marks LB; Mruthyunjaya P; Kirsch DG Int J Radiat Oncol Biol Phys; 2014 May; 89(1):127-36. PubMed ID: 24613808 [TBL] [Abstract][Full Text] [Related]
39. Eyelids metastases from uveal melanoma: clinical and histopathologic features of two cases and literature review. Martel A; Oberic A; Moulin A; Zografos L; Hamedani M Eye (Lond); 2019 May; 33(5):767-771. PubMed ID: 30560912 [TBL] [Abstract][Full Text] [Related]
40. Evaluation of HSP-27, BAP1, BRAF V600E, CCR7, and PD-L1 expression in uveal melanoma on enucleated eyes and metastatic liver tumors. Ağın A; Kiratli H; Guresci S; Babaoglu B; Karakaya J; Soylemezoglu F Int J Biol Markers; 2022 Jun; 37(2):200-209. PubMed ID: 35341390 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]